**Appendix No. 15 - Numbers and Percentages of Cancer Patients discussed in Tumor Boards**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **1** | **2** | **3** | **4** | **5** | **6** | **7** |
| **Disease site** | Number of all cancer patients treated in the cancer center in 2019 | Patients discussed in tumor board | Patients discussed in tumor board | %  columns  2/1 | Number of cancer patients newly diagnosed in 2019 | Patients  discussed in tumor board | %  column  5/4 |
|  |  |  |  |  |  |  |  |
| Lymphoid leukemias |  |  |  |  |  |  |  |
| Acute myeloid leukemias |  |  |  |  |  |  |  |
| Hodgkin lymphomas |  |  |  |  |  |  |  |
| Non-Hodgkin lymphomas (except Burkitt lymphoma) |  |  |  |  |  |  |  |
| Astrocytomas |  |  |  |  |  |  |  |
| Intracranial and intraspinal embryonal tumors |  |  |  |  |  |  |  |
| Neuroblastoma and ganglioneuroblastoma |  |  |  |  |  |  |  |
| Retinoblastoma |  |  |  |  |  |  |  |
| Nephroblastoma and other nonepithelial renal tumors |  |  |  |  |  |  |  |
| Osteosarcomas |  |  |  |  |  |  |  |
| Rhabdomyosarcomas |  |  |  |  |  |  |  |
| Germ cell tumors, trophoblastic tumors, and neoplasms of gonads |  |  |  |  |  |  |  |
| Others\*/\*\*\* |  |  |  |  |  |  |  |
| Total |  |  |  |  |  |  |  |

**Column 1:** Number of all cancer patients treated in the cancer center in 2019. Please transfer the numbers from appendix 3/column 1.

**Column 2:** How many of the column 1 patients were discussed in tumor boards in 2019?Do not include any patient more than once unless he/she was treated for more than one malignancy in 2019.

**Column 3:** Percentage of cancer patients discussed in tumor boards (column 2/1).

**Column 4:** Number of cancer patients newly diagnosed in 2019. Please transfer the numbers from appendix 3/column 2.

**Column 5:** How many of the column 4 patients were discussed in tumor boards in 2019?Do not include any patient more than once unless he/she was treated for two malignancies in 2019.

**Column 6:** Percentage of cancer patients discussed in tumor boards (column 5/4).